A. Napolitano

Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer

A. Rossi, C. Gridelli, P. Maione, 2016, Expert opinion on biological therapy.

Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients

B. Vincenzi, G. Tonini, R. Addeo, 2011 .

The PI3k inhibitors: new hopes in the battle against advanced NSCLC.

A. Rossi, C. Gridelli, P. Maione, 2014, Frontiers in bioscience.

The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer

A. Rossi, C. Gridelli, F. Ciardiello, 2013 .

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC

A. Rossi, C. Gridelli, F. Ciardiello, 2013, Targeted Oncology.

Current challenges of lung cancer care in an aging population

A. Rossi, C. Gridelli, P. Maione, 2015, Expert review of anticancer therapy.

Agents in the preclinical development stage for non-small cell lung cancer

A. Rossi, C. Gridelli, P. Maione, 2015, Expert review of anticancer therapy.

The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.

A. Rossi, C. Gridelli, P. Maione, 2012, Current medicinal chemistry.